Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Targeted CAR-T Cell Therapy (IVS-3001) for the Treatment of Previously Treated Locally Advanced Unresectable or Metastatic HLA-G Positive Solid Tumors

Trial Status: active

This phase I/IIa trial studies the side effects and best dose of IVS-3001 and to see how well it works in treating patients with previously treated HLA-G positive solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery (unresectable) or that have spread from where it first started (primary site) to other places in the body (metastatic). IVS-3001 is a type of chimeric antigen receptor (CAR) T-cell therapy in which a patient's lymphocytes (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. To make IVS-3001, white blood cells (lymphocytes) are collected from the patient's blood and then genetically changed in a lab by injecting them with a special kind of virus. After the cells are changed in the lab, it is known as IVS-3001. IVS-3001 is designed to target and destroy cancer cells that carry the HLA-G protein on them.